“We found a strong correlation between sustained minimal residual disease negativity and prolonged survival,” said C. Ola Landgren, MD, PhD, chief of the Division of Myeloma at Sylvester. “In fact, patients who were treated with modern combination therapy and achieved and sustained MRD negativity for at least two years were highly likely to remain free from multiple myeloma 10 years later.”